ATE246920T1 - Liposomenzubereitungen zur behandlung von viruserkrankungen - Google Patents

Liposomenzubereitungen zur behandlung von viruserkrankungen

Info

Publication number
ATE246920T1
ATE246920T1 AT95932599T AT95932599T ATE246920T1 AT E246920 T1 ATE246920 T1 AT E246920T1 AT 95932599 T AT95932599 T AT 95932599T AT 95932599 T AT95932599 T AT 95932599T AT E246920 T1 ATE246920 T1 AT E246920T1
Authority
AT
Austria
Prior art keywords
treatment
liposomes
formulations
hiv
antiviral
Prior art date
Application number
AT95932599T
Other languages
English (en)
Inventor
Michel G Bergeron
Andre Desormeaux
Original Assignee
Infectio Recherche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infectio Recherche Inc filed Critical Infectio Recherche Inc
Application granted granted Critical
Publication of ATE246920T1 publication Critical patent/ATE246920T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95932599T 1994-10-03 1995-10-03 Liposomenzubereitungen zur behandlung von viruserkrankungen ATE246920T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31673594A 1994-10-03 1994-10-03
PCT/CA1995/000561 WO1996010399A1 (en) 1994-10-03 1995-10-03 Liposome-formulations for treatment of viral diseases

Publications (1)

Publication Number Publication Date
ATE246920T1 true ATE246920T1 (de) 2003-08-15

Family

ID=23230423

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95932599T ATE246920T1 (de) 1994-10-03 1995-10-03 Liposomenzubereitungen zur behandlung von viruserkrankungen

Country Status (15)

Country Link
US (1) US5773027A (de)
EP (1) EP0784470B1 (de)
JP (1) JPH10506396A (de)
CN (1) CN1165480A (de)
AT (1) ATE246920T1 (de)
AU (1) AU714043B2 (de)
BR (1) BR9509217A (de)
CA (1) CA2201631C (de)
DE (1) DE69531499T2 (de)
ES (1) ES2204964T3 (de)
MX (1) MX9702435A (de)
NO (1) NO971494L (de)
NZ (1) NZ293216A (de)
PT (1) PT784470E (de)
WO (1) WO1996010399A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9605437D0 (en) * 1996-03-15 1996-05-15 Iaf Biochem Int Cytomegalovirus inhibiting compounds
US6207185B1 (en) 1996-03-22 2001-03-27 Bio-Sphere Technology Method for inducing a systemic immune response to an HIV antigen
US6117449A (en) * 1996-03-22 2000-09-12 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to a hepatitis antigen
US6015576A (en) * 1997-08-29 2000-01-18 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to an antigen
CA2270600A1 (en) * 1999-05-03 2000-11-03 Infectio Recherche Inc. Method and formulations for the treatment of diseases, particularly those caused by human immunodeficiency virus and leishmania
US8518437B2 (en) * 2001-11-13 2013-08-27 Celator Pharmaceuticals, Inc. Lipid carrier compositions with enhanced blood stability
WO2003041682A2 (en) * 2001-11-13 2003-05-22 Celator Technologies, Inc. Lipid carrier compositions and methods for improved drug retention
US20040208921A1 (en) * 2003-01-14 2004-10-21 Ho Rodney J. Y. Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
US20130085146A1 (en) * 2003-01-14 2013-04-04 Rodney J.Y. Ho Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
US8986731B2 (en) * 2003-08-26 2015-03-24 Biolitec Pharma Marketing Ltd Pegylated liposomal formulations of hydrophobic photosensitizers for photodynamic therapy
US20050048109A1 (en) * 2003-08-26 2005-03-03 Ceramoptec Industries, Inc. Non-polar photosensitizer formulations for photodynamic therapy
CN101588813A (zh) * 2005-04-12 2009-11-25 杜克大学 诱导人类免疫缺陷病毒的中和抗体的方法
CN101861143B (zh) * 2007-11-15 2015-09-09 拜莱泰克制药市场有限公司 用于炎性疾病的光动力治疗的聚乙二醇化脂质体制剂
US9040079B2 (en) * 2007-11-19 2015-05-26 Biolitec Pharma Marketing Ltd Pegylated compounds for age-related macular degeneration
DK177532B1 (en) * 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
EP3084431B1 (de) 2013-12-20 2018-11-07 Roche Diagnostics GmbH Verbindungen mit einer oder mehreren hydrophoben domänen und hydrophile domäne mit zum binden von zellen geeigneten peg-elementen
WO2015091948A1 (en) 2013-12-20 2015-06-25 Roche Diagnostics Gmbh Method of immobilizing a cell on a support using compounds comprising a polyethylene glycol moiety
JP6461973B2 (ja) * 2013-12-20 2019-01-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ２以上の疎水性ドメインおよびｐｅｇ部分を含む親水性ドメインを含む化合物の、細胞の安定化のための使用
RU2669773C1 (ru) * 2017-05-30 2018-10-16 Федеральное государственное бюджетное учреждение "3 Центральный научно-исследовательский институт" Министерства обороны Российской Федерации Способ определения модуля скорости неманеврирующей аэродинамической цели по выборкам измерений дальности
CN116056759A (zh) * 2020-08-24 2023-05-02 叶秩光 超声波搭配微气泡辅助的气球导管系统及其血管扩张方法
EP4108251A1 (de) 2021-06-22 2022-12-28 Solmic Biotech GmbH Griffithsin zur verwendung in einem verfahren zur vorbeugung oder behandlung von infektionen mit respiratorischen viren
EP4306130A1 (de) 2022-07-11 2024-01-17 Solmic Biotech GmbH Inhalierbare formulierung zur verwendung bei der behandlung von bakteriellen lungeninfektionen

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4416872A (en) * 1982-03-17 1983-11-22 The United States Of America As Represented By The Secretary Of The Army Treatment of malaria with liposomes containing 8-aminoquinoline derivatives and glycoconjugates
US5254539A (en) * 1985-08-26 1993-10-19 U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health Method of treating HIV with 2',3'-dideoxyinosine
IL86009A (en) * 1987-04-10 1991-09-16 Us Health Liposome-encapsulated phosphorylated nucleosides for treatment of retroviral diseases
US4997761A (en) * 1987-10-06 1991-03-05 Houston Biotechnology Incorporated Phosphatidyl treatment of viral disease
ZA902710B (en) * 1989-05-22 1991-12-24 Univ Georgia Res Found Enzyme luminescence assay
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5843473A (en) * 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues

Also Published As

Publication number Publication date
WO1996010399A1 (en) 1996-04-11
EP0784470B1 (de) 2003-08-13
NZ293216A (en) 1999-03-29
EP0784470A1 (de) 1997-07-23
CN1165480A (zh) 1997-11-19
DE69531499D1 (de) 2003-09-18
CA2201631C (en) 2004-05-04
CA2201631A1 (en) 1996-04-11
MX9702435A (es) 1997-06-28
JPH10506396A (ja) 1998-06-23
AU714043B2 (en) 1999-12-16
US5773027A (en) 1998-06-30
NO971494L (no) 1997-05-27
BR9509217A (pt) 1998-01-27
DE69531499T2 (de) 2004-06-24
AU3560395A (en) 1996-04-26
ES2204964T3 (es) 2004-05-01
PT784470E (pt) 2003-12-31
NO971494D0 (no) 1997-04-02

Similar Documents

Publication Publication Date Title
ATE246920T1 (de) Liposomenzubereitungen zur behandlung von viruserkrankungen
DK0774959T3 (da) Liposomalt indgivelsessystem for biologisk aktive midler
SE9703191L (sv) Läkemedel för förbättring av muskelfunktionsdurationen eller behandling av muskelstörningar eller -sjukdom
ATE309798T1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
ES2150595T3 (es) Procedimiento de preparacion de un vector viral de por lo menos 20 kb por recombinacion homologa intermolecular en una celula procariota.
CA2258811A1 (en) Formulation for use in the prevention of pathogen induced diseases including hiv and hsv
ATE152614T1 (de) Mittel zur behandlung entzündeter gewebe
CA2197319A1 (en) Lipid analogs for treating viral infections
IL112667A0 (en) 6-substituted derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
DE59005281D1 (de) Pharmazeutische präparate.
WO2000066173A3 (en) Targeting of infectious agents bearing host cell proteins
GEP20022751B (en) Aqueous Pharmaceutical Composition Comprising an Active Ingredient Which Is Highly Insoluble in Water
WO1994027584A3 (en) Arylating medicaments
RU98111152A (ru) Применение активного вещества флупиртина или его фармакологически приемлемых солей в качестве лекарственного средства для профилактики и лечения заболеваний, ассоциированных с повреждением клеточной системы гемопоэза
HUP9900945A2 (hu) Nukleozidanalógok herpes simplex vírus fertőzések kombinációs terápiájában
CA2091134A1 (en) Therapeutic agent for threatened abortion
IL106491A0 (en) Anti viral preparations
HUP0100937A2 (hu) Többszörösen elágazó peptidkonstrukciókat tartalmazó liposzómák és alkalmazásuk humán immundeficiencia vírus ellen
Murphy New antiretroviral drugs part I: PIs
DE69926633D1 (de) Injizierbare arzneiformulierungen von partricin derivaten
AU2229997A (en) Pharmaceutical compositions comprising natural human alpha-interferon
RU95102712A (ru) Липосомный фармацевтический препарат и лечебно-профилактический крем на его основе
Hannig et al. Surfactant therapy after electroporation mediated muscle injury in vivo
IT1277609B1 (it) Apparecchiatura per l'inattivazione virale di hiv in emoderivati e per supporto a trattamenti terapeutici di affezioni virali da hiv

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties